EMAIL THIS PAGE TO A FRIEND

PloS one

Binge Ethanol and MDMA Combination Exacerbates Toxic Cardiac Effects by Inducing Cellular Stress.


PMID 26509576

Abstract

Binge drinking is a common pattern of ethanol consumption among young people. Binge drinkers are especially susceptible to brain damage when other substances are co-administered, in particular 3,4 methylendioxymethamphetamine (MDMA). The aim of the present work was to study the mechanisms implicated in the adaptive changes observed after administration of these drugs of abuse. So, we have evaluated the cardiac sympathetic activity and the expression and activation of heat shock protein 27 (HSP27), after voluntary binge ethanol consumption, alone and in combination with MDMA. Both parameters are markers of stressful situations and they could be modified inducing several alterations in different systems. Adolescent mice received MDMA, ethanol or both (ethanol plus MDMA). Drinking in the dark (DID) procedure was used as a model of binge. Noradrenaline (NA) turnover, tyrosine hydroxylase (TH), TH phosphorylated at serine 31 and HSP27 expression and its phosphorylation at serine 82 were evaluated in adolescent mice 48 h, 72 h, and 7 days after treatments in the left ventricle. NA and normetanephrine (NMN) were determined by high-performance liquid chromatography (HPLC); TH and HSP27 expression and phosphorylation were measured by quantitative blot immunollabeling using specific antibodies. Ethanol and MDMA co-administration increased NA turnover and TH expression and phosphorylation versus the consumption of each one of these drugs. In parallel with the described modifications in the cardiac sympathetic activity, our results showed that binge ethanol+MDMA exposure is associated with an increase in HSP27 expression and phosphorylation in the left ventricle, supporting the idea that the combination of both drugs exacerbates the cellular stress induced by ethanol or MDMA alone.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

295272
1,1-Difluoroethylene, ≥99%
C2H2F2
SAB1306362
ANTI-HSP27 (CENTER) antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB4501456
Anti-HSP27 antibody produced in rabbit, affinity isolated antibody
SAB4501457
Anti-HSP27 antibody produced in rabbit, affinity isolated antibody
SAB4300495
Anti-HSPB1 (Ab-78) antibody produced in rabbit, affinity isolated antibody
SAB4300496
Anti-HSPB1 (Ab-82) antibody produced in rabbit, affinity isolated antibody
AV09060
Anti-HSPB1 (AB1) antibody produced in rabbit, IgG fraction of antiserum
AV30177
Anti-HSPB1 (AB2) antibody produced in rabbit, IgG fraction of antiserum
HPA000497
Anti-HSPB1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2701965
Anti-HSPB1 antibody produced in rabbit
HPA038889
Anti-HSPB2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB5200099 Anti-HSPB2 antibody produced in rabbit, 1 mg/mL, affinity isolated antibody
SAB4501458
Anti-HSPB2, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4504434
Anti-phospho-HSP27 (pSer82) antibody produced in rabbit, affinity isolated antibody
SAB4300197
Anti-phospho-HSPB1 (pSer82) antibody produced in rabbit, affinity isolated antibody
SAB3701437
Monoclonal Anti-HSP27 antibody produced in mouse, clone G3.1, purified immunoglobulin
P0878
O-Phospho-L-serine
C3H8NO6P